[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5699 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 5699

 To provide programs to assist diagnosis, awareness, and education of 
             blood clot conditions, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 26, 2023

  Ms. Blunt Rochester (for herself, Mr. Bucshon, Mr. Burgess, and Mr. 
    Tonko) introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To provide programs to assist diagnosis, awareness, and education of 
             blood clot conditions, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Charles Rochester Blood Clot 
Prevention and Treatment Act''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Deep venous thrombosis (in this Act referred to as 
        ``DVT'') occurs when blood clots form in the legs, pelvis, or 
        arms, and the most serious complications occur when a part of 
        the clot breaks off and travels to the lungs, causing a 
        blockage called pulmonary embolism (in this Act referred to as 
        ``PE'').
            (2) According to the Centers for Disease Control and 
        Prevention, 1 American dies every 6 minutes as a result of a 
        blood clot, and 1 in 4 people who have a PE die without 
        warning.
            (3) The Centers for Disease Control and Prevention has 
        estimated that about 900,000 people suffer from DVT/PE per year 
        and 100,000 people die each year from blood clots, but also 
        recognizes that the precise number of people affected by DVT/PE 
        is unknown.
            (4) These numbers are estimated because currently there is 
        no systematic collection of DVT/PE-related morbidity or 
        mortality data in the United States.
            (5) Blood clots can affect anyone, but certain risk factors 
        make certain individuals more susceptible, including pregnancy, 
        cancer, hospitalizations, obesity, older age, and African 
        American race.
            (6) The overall incidence of DVT and PE is 30 to 60 percent 
        higher in Black Americans, who also have a higher rate of 30-
        day mortality compared with White Americans.
            (7) The direct and indirect cost of blood clots is more 
        than $10,000,000,000 annually.
            (8) Early diagnosis of a DVT is one of the most important 
        factors in preventing a PE.

SEC. 3. PUBLIC EDUCATION, AWARENESS, AND DIAGNOSIS OF DVT/PE.

    Part J of title III of the Public Health Service Act (42 U.S.C. 
280b et seq.) is amended by inserting after section 393D the following:

``SEC. 393E. PREVENTION OF MORBIDITY AND MORTALITY AS A RESULT OF DEEP 
              VENOUS THROMBOEMBOLISM.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, (in this section 
referred to as the `Secretary') shall carry out projects to increase 
education, awareness, or diagnosis of deep venous thrombosis (in this 
section referred to as `DVT') or pulmonary embolism (in this section 
referred to as `PE') and to reduce the incidence of morbidity and 
mortality caused by blood clots. Such projects may be carried out by 
the Secretary directly or through awards of grants or contracts to 
public or nonprofit private entities. The Secretary may directly (or 
through such awards) provide technical assistance with respect to the 
planning, development, and operation of such projects.
    ``(b) Projects.--A project under this section may include--
            ``(1) the implementation of public information and 
        education programs for--
                    ``(A) the prevention of death from DVT/PE;
                    ``(B) broadening the awareness of the public 
                concerning--
                            ``(i) the risk factors for and the symptoms 
                        of DVT/PE;
                            ``(ii) target populations with greater risk 
                        for DVT/PE, including women, seniors, cancer 
                        patients, hospitalized patients, pregnant and 
                        postpartum women, Black Americans, and those in 
                        rural areas; and
                            ``(iii) the public health consequences of 
                        DVT/PE; and
                    ``(C) increasing screening, detection, and 
                diagnosis of DVT/PE; and
            ``(2) surveillance of the prevalence and incidence of DVT/
        PE to improve patient outcomes.
    ``(c) Grant and Contract Prioritization.--The Secretary may, in 
awarding grants or entering into contracts under this section, give 
priority to entities seeking to carry out projects that target the 
populations referred to in subsection (b)(1)(B)(ii).
    ``(d) Coordination of Activities.--The Secretary shall ensure that 
projects carried out under this section are coordinated, as 
appropriate, with other agencies of the Public Health Service that 
carry out activities regarding DVT/PE.
    ``(e) Best Practices.--The Secretary shall--
            ``(1) collect and analyze the findings of research 
        conducted with respect to DVT/PE; and
            ``(2) taking into account such findings, publish on the 
        website of the Centers for Disease Control and Prevention best 
        practices for physicians and other health care providers who 
        provide care to individuals with DVT/PE.''.

SEC. 4. ADVISORY COMMITTEE FOR DVT/PE PREVENTION.

    (a) Establishment.--Not later than 180 days after the date of 
enactment of this Act, the Secretary of Health and Human Services (in 
this section referred to as the ``Secretary'') shall establish an 
advisory committee to be known as the ``Advisory Committee for DVT/PE 
Prevention'' (in this section referred to as the ``Advisory 
Committee'').
    (b) Duties.--The Advisory Committee shall--
            (1) identify the aggregate number of individuals in the 
        United States who experience DVT/PE annually;
            (2) identify how data are collected regarding DVT/PE and 
        the adverse outcomes associated with such conditions;
            (3) identify how DVT/PE impacts the lives of individuals in 
        the United States;
            (4) identify the standard of care for DVT/PE surveillance, 
        detection, and treatment;
            (5) identify emerging treatments, therapies, and research 
        relating to DVT/PE;
            (6) develop recommendations to help health care providers 
        identify patients who may be at a higher risk of forming DVT/PE 
        in health care facilities;
            (7) develop recommendations to help improve patient 
        awareness of DVT/PE;
            (8) develop recommendations with respect to the standard of 
        care for patients at risk of forming DVT/PE;
            (9) develop recommendations relating to providing patients 
        and their families with written notice of increased risks of 
        forming DVT/PE; and
            (10) identify the estimated level of Federal funding needed 
        for DVT/PE services to meet the needs of high-risk populations.
    (c) Membership.--The Advisory Committee shall be composed of 
members appointed by the Secretary as follows:
            (1) At least 1 individual who has experienced blood clots.
            (2) At least 1 family member of an individual who died from 
        DVT/PE.
            (3) At least 1 health services researcher.
            (4) At least 1 health care provider.
            (5) At least 1 representative of a health plan.
            (6) At least 1 representative of a hospital or health 
        system.
            (7) At least 1 epidemiologist.
            (8) At least 1 public health expert.
            (9) At least 1 patient representative or representative of 
        a patient group.
            (10) Such individuals representing other interested parties 
        or associations, as the Secretary determines appropriate.
    (d) Report.--Not later than 18 months after the first meeting of 
the Advisory Committee, the Secretary shall submit to Congress (and 
make publicly available) a report--
            (1) summarizing the meetings and findings of the Advisory 
        Committee; and
            (2) describing the recommendations of the Advisory 
        Committee for legislative or administrative action to improve 
        DVT/PE prevention, treatment, and diagnosis, including the 
        recommendations described in paragraphs (6) through (9) of 
        subsection (b).
    (e) Termination.--The Advisory Committee shall terminate on the 
earlier of--
            (1) the date on which the Secretary submits the report 
        under subsection (d); and
            (2) the date that is 18 months after the first meeting of 
        the Advisory Committee.

SEC. 5. DVT/PE SURVEILLANCE STUDY AND REPORT.

    (a) Study.--The Secretary of Health and Human Services (in this 
section referred to as the ``Secretary'') shall conduct or support a 
study on model systems of DVT/PE surveillance, including the use of 
electronic medical record-based methods of detecting DVT and PE 
International Classification of Diseases codes (commonly known as ``ICD 
codes'') or other population-based surveillance.
    (b) Report.--Not later than 1 year after the date of enactment of 
this Act, the Secretary shall submit to Congress and the Advisory 
Committee for DVT/PE Prevention established under section 4(a) a report 
detailing the results of the study under subsection (a).

SEC. 6. AUTHORIZATION OF APPROPRIATIONS.

    There is authorized to be appropriated to carry out this section 
$20,000,000 for each of fiscal years 2025 through 2029.
                                 <all>